AZ combination COPD therapy secures okay outcome from IQWiG
This article was originally published in Scrip
Executive Summary
AstraZeneca's chronic obstructive pulmonary disease combination therapy Duaklir Genuair (aclidinium bromide/formoterol fumarate) has been granted a so-so outcome by Germany's health technology appraisal body IQWiG.